Аннотация
Неоптерин – пуриновый нуклеотид, продуцируемый в ответ на воспалительные реакции. При любом состоянии, связанном с активацией иммунного ответа и воспалением, уровень неоптерина значительно повышается. Поскольку патофизиологические аспекты сердечной недостаточности включают воспалительные реакции, логично, что уровни неоптерина должны быть высокими у пациентов с данной патологией. Цель представленного обзора литературы – рассмотреть неоптерин в качестве нового маркера при сердечной недостаточности. Проведенные к настоящему времени исследования, посвященные неоптерину, указывают на потенциально важную диагностическую и прогностическую значимость оценки данного маркера у пациентов с сердечной недостаточностью. Дальнейшие научно-клинические исследования, возможно, продемонстрируют еще более убедительные перспективы использования неоптерина в качестве дополнительного лабораторного инструмента для диагностики, стратификации риска и прогнозирования неблагоприятных сердечно-сосудистых событий у больных с сердечной недостаточностью. Определение концентраций неоптерина для оценки эффективности лекарственной терапии при сердечной недостаточности еще предстоит дополнительно изучить, чтобы сделать окончательный вывод.
Список литературы
1. Heidenreich P.A., Bozkurt B., Aguilar D., Allen L.A., Byun J.J., Colvin M.M. et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145 (18): e876-e894. DOI:10.1161/CIR.0000000000001062.
2. Chen J., Aronowitz P. Congestive Heart Failure. Med. Clin. North Am. 2022; 106(3): 447-58. DOI: 10.1016/j.mcna.2021.12.002.
3. Emmons-Bell S., Johnson C., Roth G. Prevalence, incidence and survival of heart failure: a systematic review. Heart. 2022; 108 (17): 1351-60. DOI: 10.1136/heartjnl-2021-320131.
4. Savarese G., Becher P.M., Lund L.H., Seferovic P., Rosano G.M.C. et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc. Res. 2023; 118 (17): 3272-87. DOI: 10.1093/cvr/cvac013.
5. Paraskevaidis I., Farmakis D., Papingiotis G., Tsougos E. Inflammation and Heart Failure: Searching for the Enemy-Reaching the Entelechy. J. Cardiovasc. Dev. Dis. 2023; 10 (1): 19. DOI: 10.3390/jcdd10010019.
6. Halade G.V., Lee D.H. Inflammation and resolution signaling in cardiac repair and heart failure. EBioMedicine. 2022; 79: 103992. DOI: 10.1016/j.ebiom.2022.103992.
7. Tezcan D., Onmaz D.E., Sivrikaya A., Hakbilen S., Korez M.K., Gulcemal S. et al. Assessment of serum neopterin and calprotectin as biomarkers for subclinical inflammation in patients with familial Mediterranean fever. Ir. J. Med. Sci. 2022: 1–8. DOI: 10.1007/s11845-022-03173-w.
8. Dogheim G.M., Amralla M.T., Werida R.H. Role of neopterin as an inflammatory biomarker in congestive heart failure with insights on effect of drug therapies on its level. Inflammopharmacology. 2022; 30 (5): 1617-22. DOI: 10.1007/s10787-022-01028-5.
9. Midttun O., Ulvik A., Meyer K., Zahed H., Giles G.G., Manjer J. et al. A cross-sectional study of inflammatory markers as determinants of circulating kynurenines in the Lung Cancer Cohort Consortium. Sci. Rep. 2023; 13 (1): 1011. DOI: 10.1038/s41598-023-28135-9.
10. Sakurai A., Goto M. Neopterin: isolation from human urine. J. Biochem. 1967; 61 (1): 142-5. DOI: 10.1093/oxfordjournals.jbchem. a128513.
11. Watanabe T. Neopterin derivatives — a novel therapeutic target rather than biomarker for atherosclerosis and related diseases. Vasa. 2021; 50 (3): 165-73. DOI: 10.1024/0301-1526/a000903.
12. Gieseg S.P., Baxter-Parker G., Lindsay A. Neopterin, Inflammation, and Oxidative Stress: What Could We Be Missing? Antioxidants (Basel). 2018; 7 (7): 80. DOI: 10.3390/antiox7070080.
13. Moens A.L., Kass D.A. Tetrahydrobiopterin and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2006; 26 (11): 2439-44. DOI: 10.1161/01.ATV.0000243924. 00970.cb.
14. Baxter-Parker G., Prebble H.M., Cross S., Steyn N., Shchepetkina A., Hock B.D. et al. Neopterin formation through radical scavenging of superoxide by the macrophage synthesised antioxidant 7,8-dihydroneopterin. Free Radic. Biol. Med. 2020; 152: 142-51.
DOI: 10.1016/j.freeradbiomed.2020.03.002.
15. Bendall J.K., Douglas G., McNeill E., Channon K.M., Crabtree M.J. Tetrahydrobiopterin in cardiovascular health and disease. Antioxid. Redox. Signal. 2014; 20 (18): 3040-77. DOI: 10.1089/ars.2013.5566.
16. Cunnington C., Van Assche T., Shirodaria C., Kylintireas I., Lind- say A.C., Lee J.M. et al. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation. 2012; 125 (11): 1356-66. DOI:10.1161/CIRCULATIONAHA.111.038919.
17. Prasanna J.S., Sumadhura C., Karunakar P. Neopterin as a diagnostic biomarker for diagnosis of inflammatory diseases like periodontitis. J. Oral. Res. Rev. 2017; 9: 45–9.
18. Peng Q.L., Zhang Y.M., Liang L., Liu X., Ye L.F., Yang H.B. et al. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermato-myositis. Clin. Exp. Immunol. 2020; 199 (3): 314-25. DOI: 10.1111/cei.13404.
19. Labouret M., Costi S., Bondet V., Trebossen V., Le Roux E., Ntorkou A. et al. Juvenile Neuropsychiatric Systemic Lupus Erythematosus: Identification of Novel Central Neuroinflammation Biomarkers. J. Clin. Immunol. 2023; 43(3):615-24. DOI: 10.1007/s10875-
022-01407-1. DOI: 10.1007/s10875-022-01407-1.
20. Videm V., Houge I.S., Liff M.H., Hoff M. Inflammation mediates approximately one quarter of excess relative all-cause mortality in persons with rheumatoid arthritis: the Trondelag Health Study. Sci. Rep. 2022; 12 (1): 18599. DOI: 10.1038/s41598-022-21977-9.
21. Heneberk O., Vernerova A., Kujovska Krcmova L., Wurfelova E., Radochova V. Neopterin levels in periodontitis and after nonsurgical periodontal therapy: evaluation of gingival crevicular fluid, oral fluid, serum and urinary samples-A case-control study. Biomedicines. 2022; 10 (12): 3200. DOI: 10.3390/biomedicines10123200.
22. Lee J.E., Oh T.J., Moon J.H., Park K.S., Jang H.C., Choi S.H. Serum Neopterin Concentration and Impaired Glucose Metabolism: Relationship With β-Cell Function and Insulin Resistance. Front Endocrinol. (Lausanne). 2019; 10: 43. DOI: 10.3389/fendo.2019.00043.
23. Smukowska-Gorynia A., Marcinkowska J., Chmara E., Malaczynska-Rajpold K., Slawek-Szmyt S., Cieslewicz A. et al. Neopterin as a Biomarker in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Respiration.
2018; 96 (3): 222-30. DOI: 10.1159/000488908.
24. Pergialiotis V., Karampetsou N., Zoumpourlis P., Papantoniou N., Thomakos N., Daskalakis G. Serum neopterin levels in women with preeclampsia: a systematic review. Hypertens Pregnancy. 2018; 37 (4): 220-6. DOI: 10.1080/10641955.2018.1526300.
25. Jinkawa A., Shimizu M., Nishida K., Kaneko S., Usami M., Sakumura N. et al. Cytokine profile of macrophage activation syndrome associated with Kawasaki disease. Cytokine. 2019; 119: 52-6. DOI: 10.1016/j.cyto.2019.03.001.
26. van Dijk R.A., Rijs K., Wezel A., Hamming J.F., Kolodgie F.D., Virmani R. et al. Systematic evaluation of the cellular innate immune response during the process of human atherosclerosis. J. Am. Heart Assoc. 2016; 5 (6): e002860. DOI: 10.1161/JAHA.115.002860.
27. Shirai R., Sato K., Yamashita T., Yamaguchi M., Okano T., Watanabe-Kominato K. et al. Neopterin counters vascular inflammation and atherosclerosis. J. Am. Heart Assoc. 2018; 7 (3): e007359. DOI: 10.1161/JAHA.117.007359.
28. Janmale T., Genet R., Crone E., Flavall E., Firth C., John Pirker J. et al. Neopterin and 7,8-dihydroneopterin are generated within atherosclerotic plaque. Pteridines. 2015; 26:93–103.
29. Avci E., Karabulut A., Alp A.G., Baba B., Bilgi C. Crucial markers showing the risk of coronary artery disease in obesity: ADMA and neopterin. J. Med. Biochem. 2020; 39 (4): 452-9. DOI: 10.5937/jomb0-24683.
30. Lee J.E., Oh T.J., Moon J.H., Park K.S., Jang H.C., Choi S.H. Serum Neopterin Concentration and Impaired Glucose Metabolism: Relationship With β-Cell Function and Insulin Resistance. Front Endocrinol. (Lausanne). 2019; 10: 43. DOI: 10.3389/fendo.2019.00043.
31. Sugioka K., Naruko T., Hozumi T., Nakagawa M., Kitabayashi C., Ikura Y. et al. Elevated levels of neopterin are associated with carotid plaques with complex morphology in patients with stable angina pectoris. Atherosclerosis. 2010; 208 (2): 524-30. DOI: 10.1016/j. atherosclerosis.2009.07.054.
32. Tony A.A., Tony E.A., Mohammed W.S., Kholef E.F. Evaluation of plasma levels of neopterin and soluble CD40 ligand in patients with acute ischemic stroke in upper Egypt: can they surrogate the severity and functional outcome? Neuropsychiatr. Dis. Treat. 2019;
15: 575-86. DOI: 10.2147/NDT.S177726.
33. Odegard A., Aasland J., Myhre H.O., Mollnes T.E., Videm V. The inflammatory response to stent grafting of the thoracic aorta. Int. Angiol. 2007; 26: 219-27.